J J Kavanagh
Overview
Explore the profile of J J Kavanagh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
189
Citations
1482
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Henderson T, Thorstensen J, Morrison S, Tucker M, Kavanagh J
J Neurophysiol
. 2021 Dec;
127(1):27-37.
PMID: 34851768
Although there is evidence that 5-HT acts as an excitatory neuromodulator to enhance maximal force generation, it is largely unknown how 5-HT activity influences the ability to sustain a constant...
2.
Hamilton C, Miller A, Casablanca Y, Horowitz N, Rungruang B, Krivak T, et al.
Gynecol Oncol
. 2017 Dec;
148(2):275-280.
PMID: 29195926
Objective: To identify clinicopathologic factors associated with 10-year overall survival in epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC), and to develop a predictive model identifying long-term survivors. Methods:...
3.
Cheng X, Yang G, Schmeler K, Coleman R, Tu X, Liu J, et al.
Gynecol Oncol
. 2011 Feb;
121(2):323-7.
PMID: 21277011
Objective: Endometrial stromal sarcoma (ESS) is a rare uterine malignancy. The current treatment approaches yield unsatisfactory results, and potential therapeutic targets need exploration. Methods: We reviewed the electronic medical records...
4.
Cheng X, Moroney J, Levenback C, Fu S, Jaishuen A, Kavanagh J
J Chemother
. 2009 Nov;
21(5):566-72.
PMID: 19933049
The aim of this retrospective analysis was to investigate the efficacy and adverse effects of the monoclonal antivascular endothelial growth factor antibody bevacizumab (Avastin(R)) combined with chemotherapeutic agents in non-protocol...
5.
Boruban M, Jaishuen A, Sirisabya N, Li Y, Zheng H, Deavers M, et al.
Eur J Gynaecol Oncol
. 2008 Aug;
29(4):393-6.
PMID: 18714578
Endometriosis is a common clinical disorder that shares certain characteristics, metastasis and recurrence, with malignant neoplasms. Most malignant ovarian tumors arising from endometriosis are clear cell carcinoma or endometrioid adenocarcinoma....
6.
Tao X, Kavanagh J
Int J Gynecol Cancer
. 2008 May;
18(6):1376-80.
PMID: 18462370
Long-term risk of gynecological malignancies in organ transplantation patients has increased compared with that of the general population owing to the use of immunosuppressive agents. Treatment, especially chemotherapy, in these...
7.
8.
Li Y, Hu W, Fu S, Li J, Liu J, Kavanagh J
Int J Gynecol Cancer
. 2007 Sep;
18(4):600-14.
PMID: 17894799
Estrogen plays a role in ovarian tumorigenesis. Aromatase is the enzyme required for the synthesis of estrogen via conversion of androgen to estrogen, which is the major source of estrogen...
9.
Sirisabya N, Li Y, Jaishuen A, Zheng H, Gershenson D, Kavanagh J
Int J Gynecol Cancer
. 2007 Sep;
18(4):648-51.
PMID: 17892459
Tamoxifen has been found to be safe and effective in gynecological cancer patients with normal renal function. However, to our knowledge, no data exist regarding its effectiveness and toxicity in...
10.
Kavanagh J, Sill M, Ramirez P, Warshal D, Pearl M, Morgan M
Int J Gynecol Cancer
. 2007 Sep;
18(3):460-4.
PMID: 17854432
The topoisomerase I agents are established as a therapy in recurrent ovarian cancer. Karenitecin, an analog of topotecan with solubility and pharmacologic advantages, was tested in a phase II trial...